Sébastien PELTIER (CEO) and Frédéric PELONG (CFO) participate in the BioMed Forum organized by Invest Securities to meet investors and discuss the 2023 roadmap, a year that promises to be rich in strategic advances, with:
- a decisive year in clinical terms with results expected in the first half of 2023 from the international Phase II/III REVERSE-IT study on TOTUM•63, a plant-based active substance that has already demonstrated metabolic benefits in prediabetic patients in a previous clinical study;
- the ramp-up of industrial and commercial operations with a view to supplying Nestlé Health Science with the first commercial batches of TOTUM•63 and marketing TOTUM•070 (LDL hypercholesterolemia) in France in the first half of 2024;
- the intensification of Business Development activities for the expected signature of a licensing and/or distribution partnership for TOTUM•070 internationally by the second half of 2023.